Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Merck has trailing 12 months total revenue of $59.3 billion. Its yearly revenue from Keytruda is $20.9 billion. Merck is not the same company without Keytruda. It has been demonstrated that the collaborate use of MultiKine and Keytruda would extend the patent on Keytruda by 5 years-which is expiring in 2028. Keytruda works with a high PD-L1 marker (30% of patients) and MK works with a low PD-L1 marker (70% of the patient population). This collaboration appears perfectly suited, and so, inevitable.
There was still 1 hurdle after Cel-Sci released their Phase 3 data for MultiKine. Because MK did not work with Chemotherapy it was unclear how to "write the (prescription) label" in pharma speak. By identifying the PD-L1 protein reaction this issue was solved. Simply put, anyone on a single doctor's visit can receive a routine and established P.E.T. scan and biopsy and know within 24 hours if they can/should receive MultiKine. The patients prescribed MK will have: 1) A 73% chance of living 5 years or longer. 2) The risk of death is cut by more than half at 5 years. 3) A large percentage of MK recipients will see a reduction in tumor size and stage (II, III, or IV) of the cancer. No new test or cost are required. Regulatory conditional approval pathways now exist for reasons exactly like MK. The toxicity profile of MK is nearly perfect.
No one understands that a confirmatory trial will have Surrogate (New) endpoints which are completely unlike the Phase 3 trial. One of the primary functions of the Accelerated Approval Process is to quicken the process. Tumor response is used nearly always in biological Oncology therapies. Since it is given shortly after diagnosis and should produce a tumor response in 3 weeks, this situation may move very fast.
In relation to the news this morning, Approval of the drug is given before a new confirmatory trial begins. This is the exact path that all previous Immuno Oncology drugs took.
3 Key points from the abstract: 1) Data show a 4 year survival benefit. Keytruda is 75 days. Amazing... 2) 16% of patients have a tumor response in 3 weeks vs. 0% in the control group. Amazing! 3) Very Important...If you have a tumor response you are assured of a massively improved survival. I have been told that this relationship has never before been seen. The statistics on it are amazingly good!
Phoenix2020 you are misunderstanding the daily short number. The "daily" short number is only related to market makers and their daily trading. The number which comes out every 2 weeks is the actual short interest amount.
People do not seem to notice that the trial was designed to find ANY possible benefit. The trials 2 treatment arms are different. Hence, you must analyze them separately...
40% of H&N afflicted patients are not eligible for Chemotherapy for varied reasons. Multikine will make a better world. The selloff is not surprising to me because drug benefits and risk are very esoteric and not in tune with current CVM participants.
Beautiful large breasted staff serving all kinds of crap in very risque' attire.
I just got back from the NGD shop and it is fabulous!!!! I was completely wrong about Troy being a lying crook!! This is the kind of keen business venture that will cement the Lowman legacy.
This is excellent news! Now we move to the weed business! By creating munchies, this will support the doughnut business! This Lowman individual is a friggin genius!
Can anyone answer the question?! "Did the doughnut shop open?".
Troy has talent! It is a shame he squanders it in purely fraudulent ventures.
SNM Holdings is NOW a huge success!! Troy has cash in his pocket and soon will exit personal Bankruptcy!! Now we move on to doughnuts and weed!!
TSLA=Overvalued
When the SNMN Annual report is released in April it will show the amount of SNMN stock the company sold and took as "income". In the April 2017 Annual Report the company reported $451,000. of SNMN stock sld. Now Troy finally has some cash in his wallet. This is why there will never be a real business in this "shell".
This is why the hold being lifted is so important! The following is taken directly from FDA code of regulations. It states explicitly that a primary objective of a Phase III hold is to determine the likelihood of a drug gaining approval!!
TITLE 21--FOOD AND DRUGS
CHAPTER I--FOOD AND DRUG ADMINISTRATION
DEPARTMENT OF HEALTH AND HUMAN SERVICES
SUBCHAPTER D--DRUGS FOR HUMAN USE
PART 312 -- INVESTIGATIONAL NEW DRUG APPLICATION
Subpart B--Investigational New Drug Application (IND)
Sec. 312.22 General principles of the IND submission.
(a) FDA's primary objectives in reviewing an IND are, in all phases of the investigation, to assure the safety and rights of subjects, and, in Phase 2 and 3, to help assure that the quality of the scientific evaluation of drugs is adequate to permit an evaluation of the drug's effectiveness and safety. Therefore, although FDA's review of Phase 1 submissions will focus on assessing the safety of Phase 1 investigations, FDA's review of Phases 2 and 3 submissions will also include an assessment of the scientific quality of the clinical investigations and the likelihood that the investigations will yield data capable of meeting statutory standards for marketing approval.the FDA code of regulations.
What will Troy be able to bring to the table?
What will Troy use to purchase the movie deal in Vegas? Cash? Stock?
Are you serious?I understand why you are a proud SNMN shareholder.
Bad new DJ! It is not 3/100 of a penny. IT IS 3/10000 OF A PENNY!!
Do you really think people are short snmn at .0002? It is not even legally possible to sell short a stock at thousandths of a penny. Accusing others of selling the shares short is typical excuse making when a company's stock falls.
Haha...Troy is here to pump....then dump
My prediction is that Low man gets his teat caught in a ringer with the SEC because of this scheme.
snmn will NEVER acquire anything because it has no money, ability or inclination
I am a buyer at .000000000000000000000024
Can a stock trade lower then .0001 ?
Someone please tell me what SNMN can use as payment for an acquisition.
SNMN IS A WORTHLESS COMPANY!! They have no money or ability to buy anything. Would you accept SNMN stock as payment for your company?
Troy, my friend, you played this one well so far but it is now a dead dog. Reverse this mother and you probably can get in a whole new cadre of investors. Did you make more then $45,000 in the last run-up?
Someone better hit those .0003's before they are all gone. Easy money Troy.
Typically just inane comments to a serious matter. It is manifest to anyone what this is all about.
snmn is but a mechanism for Low man to manipulate the buying and selling of shares. It is ridiculous for a company to be public with no business and a current account deficit of $70,000
Mikey501, can you explain to me how they are going to make any acquisitions?
Don't you understand. There can be no REAL news! They have no money, business, expertise to effect any transaction.
If you believe SNMN broke any security laws you can go to sec.gov They have a "Tip Line" where you can inform them of your suspicions.
They will not put out a TRUTHFUL press release because they do not have the ability to do anything that requires money. Would you accept shares of snmn as payment when the company has no money or business and a CEO of, I am being generous here, a dubious background.
ANSWER: The only way for SNMN to have any appreciable gain is.........REVERSE SPLIT